Health TrialsbyHealthPanel

Hydrogen Peroxide 40% Versus Salicylic Acid 40% for Plantar Warts

ConditionPlantar Wart
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age12+
SponsorAssiut University

About this trial

This randomized controlled trial aims to compare the efficacy and safety of topical hydrogen peroxide 40 percent versus topical salicylic acid 40 percent in the treatment of plantar warts.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age greater than or equal to 12 years of both sexes

Clinically diagnosed plantar wart or warts

Wart duration at least 2 weeks prior to enrollment

Willing and able to give written informed consent or parental consent for minors

Disqualifiers

Pregnant or lactating women

Immunocompromised patients including HIV infection organ transplant recipients or on immunosuppressive therapy

Diabetic patients with peripheral neuropathy or peripheral arterial disease

Known hypersensitivity to hydrogen peroxide or salicylic acid

Trial design

Design model

Parallel

Treatments tested in this trial

  • Hydrogen Peroxide 40%

    Drug

    Topical hydrogen peroxide 40 percent w/w solution in opaque light-protected applicator bottle applied once weekly for up to 12 weeks

  • Salicylic Acid 40%

    Drug

    Topical salicylic acid 40 percent w/w preparation applied once daily for up to 12 weeks

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Topical Hydrogen Peroxide 40%Experimental treatment 1 intervention
Group B: Topical Salicylic Acid 40%Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Number of participants with complete clinical clearance

Number of participants with complete clinical clearance defined as complete disappearance of plantar wart and restoration of normal skin markings

Time frame
At 12 weeks

Secondary outcomes

1

Time to complete clearance

Time in weeks from treatment start to complete clinical clearance

Time frame
Up to 12 weeks
2

Change in wart surface area

Change in wart surface area in square millimeters measured in two perpendicular diameters using digital caliper from baseline

Time frame
From baseline to 12 weeks
3

Treatment-related pain score

Pain score assessed using 0 to 10 Visual Analogue Scale with 0 indicating no pain and 10 indicating worst pain with higher scores indicating worse pain

Time frame
Up to 12 weeks
4

Number of participants with local adverse effects

Number of participants who develop local adverse effects including blistering hyperpigmentation scarring or secondary infection

Time frame
Up to 12 weeks

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: